Immix Biopharma - Pipeline momentum continues in FY23
Immix Biopharma’s FY22 results reflected a busy period as management ramped up clinical activity across multiple programs. In a major development,...
511 Views
Immix Biopharma - Positive data from CAR-T treatment continues
Immix Biopharma has announced additional data from the ongoing Phase Ib/II open-label NEXICART-1 trial investigating the company’s CAR-T therapy,...
471 Views
Immix Biopharma - Expanding portfolio into CAR-T cell therapy
Immix Biopharma has expanded both its clinical and technology portfolio with the in-licensing of its first CAR-T cell therapy, NXC-201. The...
572 Views
Immix Biopharma - Encouraging progress on multiple fronts
Immix Biopharma has announced interim response rate data from its newly formed subsidiary, Nexcella, concerning the BCMA-targeting cell therapy...
497 Views
Immix Biopharma - Potential upside with expansion into CAR-T
Immix Biopharma has announced the in-licensing of NXC-201, a novel chimeric antigen receptor T-cell (CAR-T) therapy, which has shown high response...
782 Views